FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Clinical trial NCT02325739 · COMPLETED

Trial details

NCT number: NCT02325739
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Solid Malignancies

Start date: 2014-12-29
Primary completion: 2019-05-30
Enrollment: 172

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.